GLP-1 Receptor Agonist Evidence Amid Gray Market Concerns
GLP-1 receptor agonist gray market use raises significant clinical concerns for prescribers. Patients may use unregulated peptides, complicating safety and dosing. Understanding these risks is essential for responsible metabolic care.
GLP-1 Receptor Agonist Evidence: Weight Loss & Marriage Risk
GLP-1 receptor agonist psychosocial outcomes are important for understanding the effects of weight loss on relationships. Significant weight loss can lead to shifts in self-perception and interpersonal dynamics. Clinicians should consider counseling…
Cannabis and Sleep: A Proposed Self-Reinforcing Cycle That May Worsen Both
The cannabis sleep cycle model proposes that sleep problems lead to cannabis self-medication, which may worsen sleep due to neurobiological tolerance. This bidirectional effect can escalate use and increase risk for cannabis use disorder. Understanding…
Cannabis and Sleep: A Self-Reinforcing Cycle That May Worsen Both
The cannabis sleep bidirectional model explains how sleep problems lead to cannabis self-medication, which may worsen sleep issues through neurobiological effects. Over time, tolerance can develop, increasing the risk for cannabis use disorder. This…
Cannabis and the Heart and Vessels: What the Science Actually Says
This 2024 narrative review explores cannabinoid involvement in atherosclerosis and other vascular diseases, highlighting both therapeutic promise and evidentiary gaps. The endocannabinoid system plays a complex role in vascular biology through multiple…